


Dropping the Bace



[Edwin Elmhirst](#)

The last of the clinical-stage beta-secretase (Bace) inhibitors in Alzheimer's disease is dead. Biogen and its partner Eisai's decision to discontinue ongoing studies of elenbecestat signals the end for this once-popular mechanism of action. Below is a summary of all the other Bace inhibitor projects that have fallen by the wayside in the past few years.

Dropping the Bace: A timeline of Bace inhibitor discontinuations



Source: EvaluatePharma

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2023 Evaluate Ltd.